218 related articles for article (PubMed ID: 15461871)
21. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
23. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis.
Marzo-Ortega H; McGonagle D; Rhodes LA; Tan AL; Conaghan PG; O'Connor P; Tanner SF; Fraser A; Veale D; Emery P
Ann Rheum Dis; 2007 Jun; 66(6):778-81. PubMed ID: 17185324
[TBL] [Abstract][Full Text] [Related]
26. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
27. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
[TBL] [Abstract][Full Text] [Related]
28. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
[TBL] [Abstract][Full Text] [Related]
29. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy.
Kamili Qu; Menter A
J Drugs Dermatol; 2010 Jan; 9(1):57-60. PubMed ID: 20120426
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.
Torii H; Nakano M; Yano T; Kondo K; Nakagawa H;
J Dermatol; 2017 May; 44(5):552-559. PubMed ID: 27882586
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
Voulgari PV; Venetsanopoulou AI; Epagelis EK; Alamanos Y; Takalou I; Drosos AA
Ann Rheum Dis; 2007 Feb; 66(2):270-1. PubMed ID: 17068063
[No Abstract] [Full Text] [Related]
33. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab).
Chan JJ; Gebauer K
Australas J Dermatol; 2003 May; 44(2):116-20. PubMed ID: 12752184
[TBL] [Abstract][Full Text] [Related]
35. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
[TBL] [Abstract][Full Text] [Related]
36. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody.
Wollina U; Konrad H
J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):127-9. PubMed ID: 12046813
[TBL] [Abstract][Full Text] [Related]
37. Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis.
Sridhar J; Desylva P; Singh YD
Indian J Dermatol Venereol Leprol; 2006; 72(2):133-5. PubMed ID: 16707820
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
39. [Infliximab: patients selection].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
